Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for NVS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 22.61%
March 31, 2026 24.07%
December 31, 2025 18.03%
September 30, 2025 28.26%
June 30, 2025 28.63%
March 31, 2025 27.27%
December 31, 2024 21.44%
September 30, 2024 24.84%
June 30, 2024 25.94%
March 31, 2024 22.72%
December 31, 2023 23.09%
September 30, 2023 12.84%
June 30, 2023 19.86%
March 31, 2023 19.91%
December 31, 2022 12.43%
September 30, 2022 12.68%
June 30, 2022 13.26%
March 31, 2022 17.71%
December 31, 2021
September 30, 2021 21.17%
June 30, 2021 22.34%
March 31, 2021 16.59%
December 31, 2020 16.44%
September 30, 2020 15.76%
June 30, 2020 16.45%
Date Value
March 31, 2020 17.69%
December 31, 2019 9.10%
September 30, 2019 16.77%
June 30, 2019 17.93%
March 31, 2019 16.74%
December 31, 2018 10.61%
September 30, 2018 17.04%
June 30, 2018 68.03%
March 31, 2018 18.03%
December 31, 2017 15.30%
September 30, 2017 16.78%
June 30, 2017 16.17%
March 31, 2017 14.43%
December 31, 2016 7.60%
September 30, 2016 16.04%
June 30, 2016 14.48%
March 31, 2016 17.34%
December 31, 2015 8.42%
September 30, 2015 14.77%
June 30, 2015 14.62%
March 31, 2015 19.28%
December 31, 2014 18.64%
September 30, 2014 23.78%
June 30, 2014 20.30%
March 31, 2014 21.17%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Roche Holding AG --
AstraZeneca PLC 20.15%
Johnson & Johnson 21.86%
Eli Lilly & Co. 30.88%
Merck & Co., Inc. -8.06%